AVALO THERAPEUTICS, INC.: 10-Q filed 2016-08-15
What AVALO THERAPEUTICS, INC. reported in its quarterly report filed 2016-08-15 (fiscal Q2 2016): 22 published measures, 55 facts as tagged in accession 0001558370-16-007985.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2016-08-15
- Fiscal period
- fiscal Q2 2016
- Accession
- 0001558370-16-007985 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AVALO THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 13,171,784 | USD | |
| At 2015-12-31 | 21,657,565 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 7,600,811 | USD | |
| At 2015-12-31 | 8,573,838 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 5,570,973 | USD | |
| At 2015-12-31 | 13,083,727 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 11,879,545 | USD | |
| At 2015-12-31 | 21,161,967 | USD | |
| At 2015-06-30 | 6,142,864 | USD | |
| At 2014-12-31 | 11,742,349 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -3,524,160 | USD | 91 |
| 2016-01-01 to 2016-06-30 | -8,664,174 | USD | 182 |
| 2015-04-01 to 2015-06-30 | -2,912,745 | USD | 91 |
| 2015-01-01 to 2015-06-30 | -6,150,464 | USD | 181 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-06-30 | 19,157 | USD | 182 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | -62,227,654 | USD | |
| At 2015-12-31 | -53,563,480 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 40,957 | USD | |
| At 2015-12-31 | 35,216 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-06-30 | 1,151,420 | USD | 182 |
| 2015-01-01 to 2015-06-30 | 292,213 | USD | 181 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -3,488,037 | USD | 91 |
| 2016-01-01 to 2016-06-30 | -8,430,405 | USD | 182 |
| 2015-04-01 to 2015-06-30 | -2,891,352 | USD | 91 |
| 2015-01-01 to 2015-06-30 | -5,375,423 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 13,130,827 | USD | |
| At 2015-12-31 | 21,622,349 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 6,585,579 | USD | |
| At 2015-12-31 | 5,849,818 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 756,464 | USD | |
| At 2015-12-31 | 678,109 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 2,501,753 | USD | 91 |
| 2016-01-01 to 2016-06-30 | 4,795,028 | USD | 182 |
| 2015-04-01 to 2015-06-30 | 1,875,294 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 3,598,606 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 8,650,143 | shares | |
| At 2015-12-31 | 8,650,143 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 67,789,977 | USD | |
| At 2015-12-31 | 66,638,557 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 404,129 | USD | |
| At 2015-12-31 | 370,538 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 541,962 | USD | |
| At 2015-12-31 | 401,550 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 1,636,772 | USD | 91 |
| 2016-01-01 to 2016-06-30 | 4,285,865 | USD | 182 |
| 2015-04-01 to 2015-06-30 | 1,016,058 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 1,776,817 | USD | 181 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-06-30 | 13,416 | USD | 182 |
| 2015-01-01 to 2015-06-30 | 11,038 | USD | 181 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -36,123 | USD | 91 |
| 2016-01-01 to 2016-06-30 | -233,769 | USD | 182 |
| 2015-04-01 to 2015-06-30 | -21,393 | USD | 91 |
| 2015-01-01 to 2015-06-30 | -775,041 | USD | 181 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-06-30 | 61,193 | USD | 182 |
| 2015-01-01 to 2015-06-30 | -3,478 | USD | 181 |
Inspect the source
- Entity
- AVALO THERAPEUTICS, INC. / CIK 0001534120
- Captured
- 2026-09-20T09:16:35.394Z
- SEC response SHA-256
c27cef5388033067af62e0489a1b2af90f086713b680df0f63e0f63ad2ea1ca3
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001534120.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))